Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/26/2025

Management of Hypercholesterolemia and Hypertriglyceridemia

Assessment of Current Lipid Profile and Risk

  • The patient has moderate hypertriglyceridemia with triglycerides of 322 mg/dL, which increases cardiovascular disease risk 1
  • Total cholesterol of 211 mg/dL is above optimal levels, and the elevated non-HDL cholesterol further increases cardiovascular risk 2, 3
  • Current psychiatric medications may be contributing to lipid abnormalities, as antipsychotics and certain psychiatric medications are known secondary causes of hypertriglyceridemia 1

Management Strategy

Step 1: Address Secondary Causes and Lifestyle Modifications

  • Evaluate the contribution of psychiatric medications to lipid abnormalities - antipsychotics like ziprasidone and tricyclic antidepressants like amitriptyline can elevate triglycerides and cholesterol 1
  • Implement intensive lifestyle interventions, including dietary counseling, weight loss, regular physical activity, and limitation of alcohol consumption 1, 4

Step 2: Pharmacological Management

  • Initiate statin therapy as first-line treatment for both elevated cholesterol and moderate hypertriglyceridemia 2, 5
  • For this patient with moderate hypertriglyceridemia, the treatment goal should be a non-HDL cholesterol level 30 mg/dL higher than the LDL goal 1

Step 3: Monitoring and Follow-up

  • Monitor lipid levels 4-12 weeks after initiating therapy 2
  • Regularly assess for potential side effects of lipid-lowering medications 2